The stock of Zymeworks BC Inc (ZYME) has seen a -7.37% decrease in the past week, with a -17.66% drop in the past month, and a -12.07% decrease in the past quarter. The volatility ratio for the week is 3.55%, and the volatility levels for the past 30 days are at 4.09% for ZYME. The simple moving average for the last 20 days is -11.17% for ZYME’s stock, with a simple moving average of -1.83% for the last 200 days.
Is It Worth Investing in Zymeworks BC Inc (NASDAQ: ZYME) Right Now?
The 36-month beta value for ZYME is at 1.14. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for ZYME is 65.94M, and currently, shorts hold a 7.63% of that float. The average trading volume for ZYME on April 19, 2024 was 567.85K shares.
ZYME) stock’s latest price update
Zymeworks BC Inc (NASDAQ: ZYME)’s stock price has dropped by -2.03 in relation to previous closing price of 8.85. Nevertheless, the company has seen a loss of -7.37% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-18 that Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company’s flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tract cancer. Zymeworks utilizes proprietary platforms to create multispecific antibody therapeutics and antibody-drug conjugate technologies for its drug candidates.
Analysts’ Opinion of ZYME
Many brokerage firms have already submitted their reports for ZYME stocks, with Wells Fargo repeating the rating for ZYME by listing it as a “Overweight.” The predicted price for ZYME in the upcoming period, according to Wells Fargo is $12 based on the research report published on March 21, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ZYME reach a price target of $8, previously predicting the price at $10. The rating they have provided for ZYME stocks is “Neutral” according to the report published on January 04th, 2023.
Jefferies gave a rating of “Buy” to ZYME, setting the target price at $11 in the report published on December 20th of the previous year.
ZYME Trading at -20.22% from the 50-Day Moving Average
After a stumble in the market that brought ZYME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.02% of loss for the given period.
Volatility was left at 4.09%, however, over the last 30 days, the volatility rate increased by 3.55%, as shares sank -19.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.21% lower at present.
During the last 5 trading sessions, ZYME fell by -7.37%, which changed the moving average for the period of 200-days by +1.05% in comparison to the 20-day moving average, which settled at $9.66. In addition, Zymeworks BC Inc saw -16.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZYME starting from Galbraith Kenneth, who sale 5,706 shares at the price of $11.22 back on Jan 08 ’24. After this action, Galbraith Kenneth now owns 23,762 shares of Zymeworks BC Inc, valued at $63,996 using the latest closing price.
Moore Paul Andrew, the Chief Scientific Officer of Zymeworks BC Inc, sale 2,339 shares at $11.22 during a trade that took place back on Jan 08 ’24, which means that Moore Paul Andrew is holding 7,367 shares at $26,233 based on the most recent closing price.
Stock Fundamentals for ZYME
Current profitability levels for the company are sitting at:
- -1.82 for the present operating margin
- -0.55 for the gross margin
The net margin for Zymeworks BC Inc stands at -1.56. The total capital return value is set at -0.26. Equity return is now at value -24.78, with -19.30 for asset returns.
Based on Zymeworks BC Inc (ZYME), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -4.43. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 19.13.
Currently, EBITDA for the company is -119.52 million with net debt to EBITDA at 1.01. When we switch over and look at the enterprise to sales, we see a ratio of 6.33. The receivables turnover for the company is 3.9for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.41.
Conclusion
In conclusion, Zymeworks BC Inc (ZYME) has had a bad performance lately. Opinion on the stock among analysts is bearish, with some giving it a “sell” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
